CPhI Worldwide, organized by UBM EMEA, announces the opening of the 2017 CPhI Pharma Awards.
Now in its 14th consecutive year, the awards have expanded to 20 categories* – accommodating the increased demand from companies across the full spectrum of pharma – with eight new additions reflecting the increased diversity of attendees at CPhI Worldwide.
The CPhI Pharma Awards, acknowledged as the most prestigious in the industry, will honor companies and individuals driving the pharma industry forward through innovations, technologies, and strategies. Last year, the awards received a record number of submissions with over 100 entries and CPhI Worldwide is expecting even greater interest in 2017.
In light of the increasingly dynamic pharma industry, new categories have been added to better mirror the market. For example, last year’s ‘Formulation and Excipients’ award is now split into two separate excellence awards, and two new categories have been created to evaluate company performance by size: ‘Pharma Company of the Year- Large’ and ‘Pharma Company of the Year- SME’.
Additionally, as the pharma industry places increased importance on sustainability, with a growing use of new practices, such as green chemistry and sustainable manufacturing, the ‘Sustainability Initiative of the Year’ award has been introduced.
A major part of CPhI Worldwide is helping its customers to expand into new markets and, this year, recognition is given to companies that have expanded internationally with the ‘Export Promotion’ award. Finally, three additional excellence awards have been created in order to reflect the growth of new audiences attending CPhI Worldwide: ‘OTC’, ‘Patent Centricity’, and ‘IT, mHealth, and Digitalization’.
Entries for the CPhI Pharma Awards are free of charge and the submission deadline is August 25th, 2017 – no entries submitted after this date will be valid for consideration – with shortlisted finalists announced September 1, 2017. The benefits of entering are recognition amongst industry peers and the senior judging panel, with the winners unveiled live at CPhI Worldwide during the CPhI Pharma Awards Gala Dinner (October 24, 2017). Finalists will also receive a unique profile of their award entry within the CPhI Show daily, and winners and finalists will be announced to the wider pharmaceutical industry media – giving these outstanding contributions the global profile they deserve.
To apply please visit http://awards.cphi.com/
* The full list of categories are:
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.